Form 4: Definium Therapeutics Insider Sells Shares for Tax Withholding

Definium Therapeutics Chief Legal Officer Mark Sullivan sold 13,008 common shares to cover tax withholding obligations under a Rule 10b5-1 plan.

Summary

• Mark Sullivan, Chief Legal Officer of Definium Therapeutics, Inc., reported a transaction on June 25, 2026.
• Sullivan sold 13,008 common shares of the company.
• The sale was to satisfy withholding tax obligations related to the settlement of vested restricted stock units.
• This transaction was executed under a Rule 10b5-1 plan adopted on March 14, 2024.
• Following this transaction, Sullivan beneficially owns 320,571 common shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as the transaction is a routine event for tax purposes under a pre-established plan and does not indicate a change in management's outlook on the company.

Negatives

• Insider selling can sometimes be perceived negatively by the market, although this sale was for tax withholding purposes and executed under a pre-established plan.

Future Outlook

The filing does not contain forward-looking statements or guidance.

Industry Context

StockSavvy.ai notes that insider transactions, particularly those related to tax withholding under Rule 10b5-1 plans, are common occurrences for executives receiving equity compensation. These transactions are typically pre-scheduled and do not necessarily reflect a change in the executive's view of the company's future prospects.

Stakeholder Impact

• Shareholders: The sale is by an insider for tax purposes under a pre-arranged plan, so it is unlikely to have a significant direct impact on the share price, though any insider selling can be a point of observation.

Key Dates

Keywords

Definium Therapeutics, DFTX, Form 4, Insider Transaction, Stock Sale, Tax Withholding, Restricted Stock Units, Rule 10b5-1 Plan, Mark Sullivan, Chief Legal Officer